Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume 109, Issue 3, Pages 159-168Publisher
WILEY
DOI: 10.1046/j.1600-0404.2003.00253.x
Keywords
epilepsy; seizure; anticonvulsant; Valproic Acid; carbamazepine; gene expression; microarray; blood marker
Categories
Funding
- NIA NIH HHS [AG19561] Funding Source: Medline
- NINDS NIH HHS [NS43252, NS28167, U10 NS077311, NS040261, NS044956] Funding Source: Medline
Ask authors/readers for more resources
Objective - Valproic acid (VPA) is a commonly used anticonvulsant with multiple systemic effects. The purpose of this pilot study is to examine the blood genomic expression pattern associated with VPA therapy in general and secondly VPA efficacy in children with epilepsy. Materials and methods - Using oligonucleotide microarrays, gene expression in whole blood was assessed in pediatric epilepsy patients following treatment with VPA compared with children with epilepsy prior to initiation of anticonvulsant therapy (drug free patients). Results - The expression of 461 genes was altered in VPA patients (n = 11) compared with drug free patients (n = 7), among which a significant number of serine threonine kinases were down-regulated. Expression patterns in children seizure free on VPA therapy (n = 8) demonstrated 434 up-regulated genes, many in mitochondria, compared with VPA children with continuing seizures (n = 3) and drug free seizure patients (n = 7). Conclusion - VPA therapy is associated with two significant and unique blood gene expression patterns: chronic VPA monotherapy in general and a separate blood genomic profile correlated with seizure freedom. These expression patterns provide new insight into previously undetected mechanisms of VPA anticonvulsant activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available